Consortium members have the
Most Pipe-Lines, Biggest Manufacturing Sites, the Highest Research capability and expenditure

Our currently running
mRNA vaccine programs
comprise of

  • Consortium members own
  • Through co-development match making programs
  • KHUB in-house developed leads from many
    research organizations worldwide

Two new autonomous, 100% in-house manufacturing sites in Korea at Local Government Special Industrial Zones are under constructions to complete the task of 5 Billion Doses mRNA vaccine supply to WHO's LMIC regions, Asia Pacific and beyond.

5
Billion Doses
mRNA vaccine supply
100
in-house
manufacturing sites

KHUB CONSORTIUM BUSINESS MODEL

is an "Infrastructure Service Provider" to help partners quickly realize the local immunization with "Pandemic-Expedited" developmental pathways. We always try to work with many national level research organizations for safer and better vaccine supplies that will bring economical answer to end pandemic globally.